Risk Factors for Voriconazole Hepatotoxicity at 12 Weeks in Lung Transplant Recipients

Antifungal Prophylaxis in Lung Transplantation-A World-wide Survey

(2011) C. F. Neoh et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

(2011) Peter F. Troke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients

(2011) Si-Hyun Kim et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Antifungal Prophylaxis with Voriconazole or Itraconazole in Lung Transplant Recipients: Hepatotoxicity and Effectiveness

(2009) J. Cadena et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Voriconazole concentrations and outcome of invasive fungal infections

(2009) S. Miyakis et al.   CLINICAL MICROBIOLOGY AND INFECTION

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

(2009) Koki Ueda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES